6/28/23, 10:09 PM EXPEDITION3 Pathway Feedback Search Clinical Topics Home Studies EXPEDITION3 EXPEDITION3 Disease Dementia Trial question What is the effect of solanezumab in patients with mild dementia due to Alzheimer's disease and with amyloid deposition? Study design Multi-center Double blinded RCT Population Characteristics of study participants 58.0% female N = 2129 42.0% male 2129 patients (1231 female, 898 male) Inclusion criteria: patients with mild dementia due to Alzheimer's disease and with amyloid deposition shown by means of florbetapir positron-emission tomography or Abeta1-42 measurements in CSF Key exclusion criteria: depression, serious or unstable medical conditions, recent infections, malignancies or psychiatric illnesses within the past 5 years, compromised renal function, clinically significant ECG abnormalities Interventions N=1057 solanezumab (intravenous infusion at a dose of 400 mg every 4 weeks for 76 weeks) N=1072 placebo (intravenous infusion every 4 weeks for 76 weeks) Primary outcome ADAS-cog14 score at 80 weeks https://web.pathway.md/studies/recynbFMZMCV2gnjE 1/2 6/28/23, 10:09 PM EXPEDITION3 Pathway 7.4 7.44 6.65 5.6 3.7 1.9 No significant difference 0.0 Solanezumab Placebo No significant difference in ADAS-cog14 score at 80 weeks (6.65 vs. 7.44; AD -0.8, 95% CI -1.73 to 0.14) Safety outcomes No significant differences in adverse events (84.5% vs. 83.4%), adverse cerebral edema or effusion (1 vs. 2 patient), serious adverse events (16.6% vs. 18.9%), deaths (0.9% vs. 1.6%). Conclusion In patients with mild dementia due to Alzheimer's disease and with amyloid deposition shown by means of florbetapir positron-emission tomography or Abeta1-42 measurements in CSF, solanezumab was not superior to placebo with respect to a ADAS-cog14 score at 80 weeks. Reference Honig LS, Vellas B, Woodward M et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):321-330. Open reference URL https://web.pathway.md/studies/recynbFMZMCV2gnjE 2/2